INMED PHARMACEUTICALS INC. Cost, Direct Material
INMED PHARMACEUTICALS INC. (INM) reported Cost, Direct Material of $40.00 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostDirectMaterial · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. cost, direct material for the quarter ending 2026-06-30 was -$360.00K.
- INMED PHARMACEUTICALS INC. cost, direct material for the quarter ending 2025-09-30 was $400.00K, a 5.27% decline year-over-year.
- INMED PHARMACEUTICALS INC. cost, direct material for the quarter ending 2024-09-30 was $422.27K, a 40.76% increase year-over-year.
- INMED PHARMACEUTICALS INC. cost, direct material for the quarter ending 2023-09-30 was $300.00K.
- INMED PHARMACEUTICALS INC. cost, direct material for fiscal 2024 was $1.50M, a 214285614.29% increase from fiscal 2023.
- INMED PHARMACEUTICALS INC. cost, direct material for fiscal 2023 was $0.70, a 100.00% decline from fiscal 2022.
- INMED PHARMACEUTICALS INC. cost, direct material for fiscal 2022 was $634.09K.
| Period end | Cost, Direct Material | Cost, Direct Material 3 month | Cost, Direct Material 9 month | Cost, Direct Material 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$360.00K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $40.00K S-4/A · filed 2026-09-09 | ||
| 2026-03-31 | $400.00K S-4 · filed 2026-07-02 | |||
| 2025-09-30 | $400.00K 10-Q · filed 2026-02-11 | $400.00K 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $200.00K S-4 · filed 2026-07-02 | |||
| 2025-03-31 | $772.00K 10-Q · filed 2025-05-12 | |||
| 2024-09-30 | $755.07K 10-Q · filed 2025-02-12 | $422.27K 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $1.50M 10-K · filed 2024-09-30 | |||
| 2023-09-30 | $300.00K 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $0.70 10-K · filed 2023-09-29 | |||
| 2022-06-30 | $634.09K 10-K · filed 2022-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |